Erik C. B. Johnson

University of Antwerp — Belgium

Medicine · Health Sciences

35h-index6.1kcitations132works11.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(74), Dementia and Cognitive Impairment Research(26), Bioinformatics and Genomic Networks(24), Metabolomics and Mass Spectrometry Studies(18), Tryptophan and brain disorders(17)

Publications127 total

Tablet‐based Cognitive Assessment Tool (TabCAT) in a multisite study of early‐onset Alzheimer's disease
Alzheimer s & Dementia·2025Open Access
Review of Artificial Intelligence for Clinical Use in Alzheimer's Disease and Related Dementias
Seminars in Neurology·2025
CSF Proteomics and Machine Learning Reveal Distinct Stages Across the Alzheimer’s Disease Continuum
2025Open Access
Voiceprints of cognitive impairment: analyzing digital voice for early detection of Alzheimer’s and related dementias
npj Dementia·2025· 1 citedOpen Access
Proteomic subtyping of Alzheimer's disease CSF links blood–brain barrier dysfunction to reduced levels of tau and synaptic biomarkers
Alzheimer s & Dementia·2025· 2 citedOpen Access
Cerebrospinal fluid proteomics for predictive assessment of Alzheimer’s Disease risk
2025· 1 citedOpen Access
Multi-scale integration of human brain vascular and CSF proteomes reveals biomarkers of cerebral amyloid angiopathy linked to Alzheimer’s disease risk
2025· 2 citedOpen Access
Multiscale proteomic modeling reveals protein networks driving Alzheimer’s disease pathogenesis
Cell·2025· 11 citedOpen Access
Plasma proteomic associations with Alzheimer’s disease endophenotypes
Nature Aging·2025· 5 citedOpen Access
APOE ε4 carriers share immune-related proteomic changes across neurodegenerative diseases
Nature Medicine·2025· 40 citedOpen Access
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging
Nature Medicine·2025· 48 citedOpen Access
Author Correction: Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
Nature Aging·2025Open Access
Genetically determined Alzheimer's disease research advances: The Down Syndrome & Autosomal Dominant Alzheimer's Disease 2024 Conference
Alzheimer s & Dementia·2025· 3 citedOpen Access
Proteomic analysis of Down syndrome cerebrospinal fluid compared to late-onset and autosomal dominant Alzheimer´s disease
Nature Communications·2025· 4 citedOpen Access
Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
Nature Aging·2025· 7 citedOpen Access
The association between pulse wave velocity and cerebrospinal fluid biomarkers for Alzheimer's disease
Journal of Alzheimer s Disease·2025· 4 cited
Amyloid <scp>PET</scp> in Sporadic Early‐ Versus Late‐Onset Alzheimer's Disease: Comparison of the <scp>LEADS</scp> and <scp>ADNI</scp> Cohorts
Annals of Neurology·2025· 6 citedOpen Access
Proteomic Subtyping of Alzheimer’s Disease CSF links Blood-Brain Barrier Dysfunction to Reduced levels of Tau and Synaptic Biomarkers
2025· 2 citedOpen Access
Characterizing and validating 12-month reliable cognitive change in Early-Onset Alzheimer's Disease for use in clinical trials
The Journal of Prevention of Alzheimer s Disease·2025· 2 citedOpen Access
Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia
Nature Medicine·2025· 16 cited
page 1 of 7Next →

Frequent Co-authors

Allan I. Levey(30), Eric B. Dammer(24), Nicholas T. Seyfried(24), James J. Lah(22), Duc M. Duong(20), Carlos Cruchaga(14), Lingyan Ping(13), Randall J. Bateman(13), Kathleen Carter(11), Jasmeer P. Chhatwal(10), Anne M. Fagan(10), Tammie L.S. Benzinger(9), Brian A. Gordon(9), Ricardo Allegri(9), Gregory S. Day(9), Luming Yin(8), Thomas S. Wingo(8), Stephen B. H. Kent(8), Celeste M. Karch(8), Jason Hassenstab(8)